DHR - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 24, 2026
6.0/10
Filing Health:GOOD

Solid fundamentals with minor concerns to monitor

Executive Summary

Significant decline in Life Sciences operating margin due to impairments and decreased sales. See detailed pass outputs for comprehensive analysis.

Top Concerns

  • !Operating profit margins declined by 130 basis points due to significant impairment charges and unfavorable cost structure impacts, though some segments saw margin improvements.
  • !The Biotechnology segment showed robust growth (+8.0%), driven by bioprocessing and consumables, while Life Sciences remained flat due to demand weakness in academic and biotech sectors.
  • !The Diagnostics segment reported modest growth (+1.5%), supported by consumables, despite pricing pressures in China related to healthcare policies.
  • !Significant goodwill balances ($43.151 billion) and finite-lived intangibles ($26.734 billion) require ongoing assessment for impairment risk.
  • !Multiple noncash impairment charges recorded for intangible assets, particularly trade names, across Life Sciences and Diagnostics segments in 2024 and 2025.

Top Positives

  • +Overall revenue grew by 3.0%, with core sales up 2.0%, driven by strong performance in the Biotechnology and Diagnostics segments.
  • +Working capital usage increased, shifting from a cash generator in 2024 to a cash user in 2025, indicating a less efficient working capital cycle this period.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

6.0/10

Management tone is cautiously measured with focus on impact of currency exchange rates.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

7.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is low with $1.3 billion in identified exposure.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows regulatory and compliance risk as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

6.0/10

Segment health analysis shows Biotechnology Segment as strongest performer while Life Sciences Segment lags.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.

Related Research

Analysis

TMO 10-K Analysis: The Three-Layer Debt Subsidy Behind 32.6× Earnings

Analysis

DHR 10-K Analysis: Why Danaher's Worst Margins Hide Its Best Cash Flows

Analysis

Amphenol's 52% Growth Created a $10.5B Question. The 10-K Answers It.